Physician profile
David L Johnson
NPI 1811942527
$851.02
in general payments reported to CMS, 2019-2025
13 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.29 · 2020: $54.88 · 2021: $32.81 · 2022: $236 · 2023: $89.13 · 2024: $211 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $208.36 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $155.23 | 2022-2025 | Eylea Hd, Eylea |
| Ocular Therapeutix, INC. | $96.66 | 2024 | Dextenza |
| Abbvie INC. | $94.94 | 2022-2025 | |
| Biogen, INC. | $79.79 | 2022 | |
| Astellas Pharma US INC | $53.24 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $44.80 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $38.96 | 2019 | |
| Boston Scientific Corporation | $28.09 | 2025 | General - Pain Management |
| Coherus Oncology, INC. | $22.59 | 2022 | |
| Alimera Sciences, INC. | $14.27 | 2024 | Yutiq, Iluvien |
| Allergan, INC. | $14.09 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.